About Lung-MAP: Leadership

Lung-MAP Partners
Leadership
This diverse, collaborative approach, with support from leading lung cancer advocacy organizations, helps to ensure that the needs of patients, clinicians, developers, and regulators are all considered in the design and operation of the trial.

– Ellen Sigal, Ph.D., Chair and Founder, Friends of Cancer Research
LUNG-MAP Study Chairs
  • ECOG-ACRIN: (Chair) Hossein Borghaei, D.O., M.S.
  • SWOG: (Vice Chair) Karen Reckamp, M.D
Lung-MAP Chair Emeritus and Senior Advisor
  • SWOG: Roy Herbst, M.D., Ph.D.
Medical Oncology Chairs/Champions
  • SWOG: David R. Gandara, M.D.
  • SWOG:  John Wrangle, M.D.
  • Alliance: Konstantin Dragnev, M.D.
  • Alliance: Jyoti D. Patel, M.D.
  • ECOG-ACRIN: Joel Neal, M.D., Ph.D.
  • ECOG-ACRIN: Ticiana Leal, M.D.
  • NRG: Martin Edelman, M.D.
  • NRG: Saiama Waqar, M.D.
Lung Cooperative Group Chairs
  • SWOG: Jhanelle E. Gray, M.D.
  • Alliance: Thomas Stinchcombe, M.D.
  • ECOG-ACRIN: Julie R. Brahmer, M.D.
  • NRG: Jeff Bradley, M.D.
Translational Medicine Chairs
  • SWOG: Fred Hirsch, M.D., Ph.D.
  • SWOG: Philip C. Mack, Ph.D.
  • Alliance: David Kozono, MD, PhD 
Biostatisticians
  • Mary Redman, Ph.D.     
  • Katherine Minichiello, M.S.         
  • Shay Bellasea, M.S.
  • Mia Hsieh, M.S.
Imaging Chairs
  • SWOG/Alliance: Lawrence H. Schwartz, M.D.
LUNG-MAP Trial Oversight Committee
  • (Co-Chair) Karen Reckamp, Director, Division of Medical Oncology/ Associate Director of Clinical Research, Cedars-Sinai – SWOG
  • (Co-Chair) Ellen Sigal, Chairperson and Founder, Friends of Cancer Research
  • (Co-Chair) Vincent Miller,  Physician-in-Chief, EQRx
  • Renzo Canetta, Former Vice President, Global R&D Oncology Policy, BMS
  • Bryan Faller, Missouri Baptist Medical Center
  • Gwen Fyfe, Former Vice President, Oncology Department, Genentech
  • Gary Gilliland, President and Director Emeritus, Fred Hutchinson Cancer Research Center
  • Gary Kelloff, Special Advisor, NCI-DCTD
  • Lisa LaVange, University of North Carolina
  • Christine Lovly, Vanderbilt University Medical Center
  • Frances A. Shepherd, CCTG, Princess Margaret Cancer Centre
  • Liza Villaruz, University of Pittsburgh Cancer Institute
  • Harpreet Singh, OCE Associate Director, FDA
  • Kim Norris, Founder and President, Lung Cancer Foundation of America
LUNG-MAP Drug Selection Committee
  • (Chair) Saiama N. Waqar, MBBS, MSCI, Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis – NRG

Voting members include representatives from each of the participating NCTN groups, FDA, NCI, Friends of Cancer Research, FNIH, key opinion leaders from academia, and drug developers from industry (retired, consultants, or not from companies participating or potentially participating in Lung-MAP).

LUNG-MAP Public Affairs Committee
  • (Chair) Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research
  • (Vice Chair) Frank DeSanto, Communications and Public Relations Manager, SWOG
  • Sam Mooney, Communications Officer, FNIH
NIH/NCI
  • Mike Miller, Senior Science Writer, NCI
  • Lynn Cave, Scientific Program Analyst, NCI-CTEP
  • Holly Massett, PhD, Senior Behavioral Science Analyst, NCI-CTEP
Lung-MAP Accrual Enhancement Committee
  • Stacey Adam, Ph.D., Associate Vice-President, Research Partnerships, Foundation for the National Institutes of Health
  • Dana Connors, M.S., PMP, Director, Cancer, Foundation for the National Institutes of Health
  • Andrea Denicoff, RN, M.S., ANP, Head, National Clinical Trials Network, Clinical Trials Operations, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program
  • Frank DeSanto, MFA (Vice Chair), Communications and Public Relations Manager, SWOG
  • Taqwa El-Hussein, Scientific Project Manager, Cancer, Foundation for the National Institutes of Health
  • Lucy Gansauer, MSN, RN, OCN, CCRP, SWOG Lung Committee, Diversity, Equity, and Inclusion Champion, (Advocate)
  • Ryan Hohman, JD, MPA (Chair), Vice President, Public Affairs, Friends of Cancer Research
  • Judy Johnson, MBA, SWOG, Lung Committee, National Cancer Institute Thoracic Malignancy Steering Committee, National Cancer Institute Patient Advocate Steering Committee, National Cancer Institute National Clinical Trials Network, Core Correlative Sciences Committee B, (Advocate)
  • Jennifer Newsome, M.S., Scientific Project Manager, Cancer, Foundation for the National Institutes of Health
  • Jennifer Pope, CCRP, Clinical Trials Team Manager, Yale University Cancer Center
  • Stephanie (Smith) Reyes, MSN, RN, OCN, Clinical Research Manager, St. Joseph’s Candler Health System, Charleston Southern University, Savannah, Georgia
  • Caroline Sigman, Ph.D., President, CCS Associates
  • Amanda Stamplis, MPH, Plain Language Writer, SWOG
  • Jamie Sundstrom, Clinical Trials Recruitment and Retention Specialist, SWOG, Cancer Research and Biostatistics
This diverse, collaborative approach, with support from leading lung cancer advocacy organizations, helps to ensure that the needs of patients, clinicians, developers, and regulators are all considered in the design and operation of the trial.

– Ellen Sigal, Ph.D., Chair and Founder, Friends of Cancer Research